Exclusive: Plenful nabs $17M to automate pharmacy operations
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Plenful, a startup that wants to free pharmacists from burdensome back-office tasks, has raised $17...
View ArticleCompugen, Nxera disclose milestone payments; Insmed aims for $650M offering
Plus, news about Celcuity and Weave Bio: Compugen bags $5M milestone from AstraZeneca: The payment was triggered after the first lung cancer patient was dosed in a Phase 3 trial of AstraZeneca’s...
View ArticleFlush with cash, Novo Nordisk Foundation now plans to reinvest some GLP-1...
The Novo Nordisk Foundation, the majority owner of Novo Nordisk, plans to put more money into regenerative medicines, including stem cells and cell therapies for a wide range of diseases. The decision,...
View ArticleNovartis ends development of KRAS drug, citing 'increasing options available'
Novartis will stop developing a KRAS lung cancer drug that had made it to Phase 3 testing, a spokesperson confirmed to Endpoints News on Thursday. The experimental medicine, known as JDQ443 or...
View Article#ASCO24: The biopharma news we’re paying attention to
More than 40,000 people are expected to congregate in Chicago this week for the American Society of Clinical Oncology’s annual meeting, and an estimated 5,800 abstracts from drug companies and...
View ArticleClik here to view.
Doctors who endorse drugs on social media are often compensated, JAMA study...
Physicians who posted endorsements of drugs on social media often received cash payments from industry, and in some cases didn’t disclose that they had been compensated, a team of researchers found in...
View ArticleAlmac’s 2023 revenue bump; France to invest in easing greenhouse gas impact
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Almac reported a 14% increase in its revenue last year, reaching £958...
View ArticleUK won’t order Grail’s cancer test for 1M people this year, a setback for...
The UK’s National Health Service will wait until 2026 before deciding whether to roll out Grail’s cancer test to one million people, a setback for Illumina and its plan to divest the diagnostics...
View ArticleFDA to begin restructuring its inspection office in October
The FDA received an official go-ahead from HHS on Thursday, setting into motion its planned reorganization of its inspection operations around the globe, with an extra focus on facility inspections,...
View ArticleBristol Myers' CAR-T therapy Breyanzi adds new approval in mantle cell lymphoma
Bristol Myers Squibb’s CAR-T therapy Breyanzi scored its third approval over the last several months, this time in the third-line setting for adults with relapsed or refractory mantle cell lymphoma, a...
View ArticleLab group sues FDA over final rule regulating laboratory-developed tests
The American Clinical Laboratory Association is arguing in a new lawsuit that the FDA has overstepped its authority by bringing laboratory-developed tests (LDTs) under its purview, the first major...
View ArticleClik here to view.
Novo Nordisk mounts legal campaign against companies marketing compounded...
Novo Nordisk is ramping up its legal campaign against medical spas, pharmacies and clinics marketing compounded versions of its popular weight loss and diabetes drugs. The Danish pharma filed nine new...
View ArticleSummit Therapeutics' stock soars as biotech says its cancer drug beat...
Hours before America’s biggest cancer conference starts in Chicago, a small biotech may have stolen the show, touting late-stage results in a Thursday afternoon press release that added over $5 billion...
View ArticleGilead’s blockbuster ADC Trodelvy fails bladder cancer confirmatory study
Gilead on Thursday disclosed that Trodelvy, the antibody-drug conjugate that is a key part of the drugmaker’s oncology business, failed a Phase 3 study after it didn’t show an improvement in patient...
View ArticleFDA delays decision on Sanofi and Regeneron's Dupixent in COPD, EMA...
Sanofi and Regeneron will have to wait three more months for a major FDA decision on expanding Dupixent’s label, the companies disclosed Friday morning. Meanwhile, European authorities have recommended...
View ArticleUltragenyx touts Phase 3 win for gene therapy in rare glycogen storage disorder
Ultragenyx’s one-time gene therapy has hit the primary endpoint in a registrational test in a rare glycogen storage disorder, triggering company plans to file with regulatory authorities next year. The...
View ArticleClik here to view.
Neurocrine CEO Kevin Gorman to retire after 32-year run; Bluebird picks up...
Kevin Gorman After more than three decades at Neurocrine, CEO Kevin Gorman will retire later this year, handing the reins of the $13 billion neuroscience drugmaker over to Kyle Gano, a longtime...
View ArticleIonis outlines Phase 3 data for rare disease drug, preps for another...
Ionis outlined full Phase 3 results for its rare disease drug donidalorsen on Friday, prepping for a potential FDA submission by the end of the year. The study is Ionis’ third Phase 3 win in the last...
View ArticleClik here to view.
Adaptimmune taps Galapagos to decentralize manufacturing of solid tumor T...
Adaptimmune Therapeutics and Galapagos have formed an alliance to manufacture a clinical-stage solid cancer asset in a decentralized way. Thad Huston At the center of the deal is Adamtimmune’s T cell...
View ArticleClik here to view.
#ASCO24: Gilead presents more data on failed Trodelvy lung cancer study
CHICAGO — Researchers on Friday afternoon pulled back the curtain on Gilead’s previously announced Phase 3 failure in certain forms of non-small cell lung cancer. Gilead’s TROP2 antibody-drug conjugate...
View Article